本帖最后由 老马 于 2012-1-13 21:20 编辑
. C4 N3 e! V, ]$ Q
/ `4 p( `# z7 [. t' K8 ]2 g6 V爱必妥和阿瓦斯丁的比较
1 ~8 c4 ^$ W z: c8 q) {1 e
& C, U! h) l2 d7 M5 l) _' n
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
1 N1 b, L1 L% o! V H/ X8 o" y
6 u' Z' L- a& \ p) @' N( G
: }" Q6 a0 v- V* u8 R
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
0 }. H, d; l* Y: w, y6 t0 j2 A! q==================================================
' ~( w, m1 P# c8 i& t6 y. P% XOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)2 U% k. j. s9 Z$ b% u/ R3 l
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 I8 H. E$ t% zResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
+ g* m) I5 a' D) O7 T1 s
|